Global Sepsis Diagnostic Market By Product (Blood Culture Media, Instruments, Assay kits & Reagents, Software), By Technology (Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry), By Method (Conventional Diagnostics, Automated Diagnostics), By Usability (Laboratory Testing, Point-of-care Testing), By Pathogen (Bacterial Sepsis, Fungal Sepsis, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030
The global sepsis diagnostic market valued at $569.49 million in 2020, and is estimated to reach $1207.58 million by 2030, growing at a CAGR of 7.8% from 2021 to 2030.
Sepsis is a life-threatening sickness that results from your body's immune system's response to an infection. Sepsis occurs when an existing infection causes the body's immune system to overreact. When an individual is sick, his/her immune system fights the infection by releasing proteins and other substances. When this response goes awry, it causes inflammation, which leads to sepsis. Bacterial infections are the most common cause of sepsis. Septic shock, a medical emergency, can result from severe sepsis. Septic shock is characterized by a fast drop in blood pressure, organ failure, and extensive tissue destruction. It can be lethal if left untreated.
The major factors that drive the growth of the global sepsis diagnostic market include increase in government funding for sepsis-related research activities and rise in prevalence of infectious diseases. In addition, increase in burden of sepsis and rise in global geriatric population propel the market growth. However, high cost of automated diagnostics devices is expected to impede the market growth. Conversely, development of rapid diagnosis/point-of-care techniques for early sepsis diagnostics is anticipated to provide lucrative opportunities to market players during the forecast period.The global sepsis diagnostic market is segmented into product type, technology, method, usability, pathogen, and region. According to product type, the market is categorized into blood culture media, instruments, assay kits & reagents, and software. By technology, it is segregated into microbiology, molecular diagnostics,immunoassays, and flow cytometry. On the basis of method, the market is categorized into conventional diagnostics and automated diagnostics. By usability, the market is bifurcated into laboratory testing and point-of-care testing. Depending on pathogen, the market is segregated into bacterial sepsis, fungal sepsis, and other pathogen. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA
The major companies profiled in the report include Abbott Laboratories, Inc., Becton, Dickinson and Company, Bruker Corporation, BioMerieux, Beckman Coulter, Inc., Danaher Corporation, Nanosphere, Inc., Hoffmann-LA Roche Ltd., T2 Biosystems Inc., Thermo Fisher Scientific Inc.
Key Market Segments
By Method
Conventional Diagnostics
Automated Diagnostics
By Product
Blood Culture Media
Instruments
Assay kits Reagents
Software
By Technology
Microbiology
Molecular Diagnostics
Immunoassays
Flow Cytometry
By Usability
Laboratory Testing
Point-of-care Testing
By Pathogen
Bacterial Sepsis
Fungal Sepsis
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
BioMerieux SA
Thermo Fisher Scientific Inc.
Abbott Laboratories, Inc.
Becton, Dickinson and Company
Bruker Corporation
Beckman Coulter, Inc.
T2 Biosystems, Inc
Nanosphere, Inc.
Hoffmann-LA Roche Ltd
Danaher Corporation
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook